SmartPharm Therapeutics Announces Presentation at the Chardan 3rd Annual Genetic Medicines Conference
CAMBRIDGE, Mass. – September 30, 2019 – SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced that José Trevejo, MD, PhD, President and Chief Executive Officer, will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7 at 8:00 a.m. ET in New York City.
A live audio webcast and replay of the presentation will be available on the “News & Events” section of the Company’s website.
About SmartPharm Therapeutics
SmartPharm Therapeutics Inc. is a privately-held, development-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of serious or rare diseases with the vision of “Biologics from Within.” The Company is currently developing a novel pipeline of non-viral, gene-encoded proteins for the treatment of conditions that require enzyme replacement therapy and tissue restoration. SmartPharm commenced operations in 2018 and is headquartered in Cambridge, MA, USA. For more information, please visit www.smartpharmtx.com.
Contacts
Investors
Ryan Baker
Argot Partners
212.600.1902 | ryan@argotpartners.com
Media
David Rosen
Argot Partners
212.600.1902 | david.rosen@argotpartners.com